[Treatment of menopausal hot flushes with a nonhormonal medication, veralipride].
The value of veralipride in menopausal disorders is no longer questionable and has been documented by a number of studies. The purpose of this paper is to study the clinical effectiveness and to look for the biological consequences of three months therapy with veralipride. To achieve this, a thorough biological study (hematology, glucids, lipids, hepatic and renal function) was done in 21 patients with a menopausal syndrome before and after taking veralipride for three months. Clinical effectiveness was excellent with 80% satisfactory results. No signs of intolerance or adverse side-effects were seen. We recorded no significant changes in biological parameters. No disturbances of renal or hepatic function were detected, either in individual assessments or in the overall statistical analysis of the study group. Because it is well tolerated, effective, and devoid of adverse metabolic side-effects, we conclude that veralipride is the best non-hormonal treatment for menopausal disorders presently available.
D002979:Climacteric / Q000187:drug effects*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008875:Middle Aged; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000627:therapeutic use
D013469:Sulpiride; C027429:veralipride
Le traitement des bouffées de chaleur de la ménopause par un médicament non hormonal, le véralipride.